Navidea Biopharmaceuticals, Inc. (NAVB)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Dec 26, 2024, 3:00 PM EST
NAVB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 0 | 0.07 | 0.53 | 0.92 | 0.66 | 1.17 | Upgrade
|
| Revenue Growth (YoY) | -99.47% | -87.65% | -41.91% | 39.10% | -43.74% | -35.41% | Upgrade
|
| Cost of Revenue | 0.05 | 0.18 | - | 0 | 0.01 | 0.1 | Upgrade
|
| Gross Profit | -0.05 | -0.12 | 0.53 | 0.91 | 0.65 | 1.07 | Upgrade
|
| Selling, General & Admin | 5.1 | 5.36 | 7.45 | 6.69 | 6.28 | 6.6 | Upgrade
|
| Research & Development | 5.09 | 5.97 | 5.14 | 4.93 | 5.34 | 4.22 | Upgrade
|
| Operating Expenses | 10.19 | 11.33 | 12.59 | 11.63 | 11.61 | 10.82 | Upgrade
|
| Operating Income | -10.24 | -11.45 | -12.06 | -10.71 | -10.96 | -9.75 | Upgrade
|
| Interest Expense | - | -0.34 | -0.01 | -0.01 | -0.01 | -0.16 | Upgrade
|
| Interest & Investment Income | 1.2 | 0.01 | 0 | 0.02 | 0.03 | 0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.17 | -0.04 | -0.01 | -0.02 | -0.01 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -9.28 | -11.81 | -12.08 | -10.72 | -10.94 | -9.78 | Upgrade
|
| Legal Settlements | -1.18 | -3.36 | - | - | - | - | Upgrade
|
| Other Unusual Items | 1.04 | - | 0.37 | - | - | -6.39 | Upgrade
|
| Pretax Income | -8.61 | -15.18 | -11.71 | -10.72 | -10.94 | -16.17 | Upgrade
|
| Income Tax Expense | - | - | 0.02 | - | 0 | -0.01 | Upgrade
|
| Earnings From Continuing Operations | -8.61 | -15.18 | -11.73 | -10.72 | -10.95 | -16.16 | Upgrade
|
| Earnings From Discontinued Operations | 7.43 | - | - | - | -0 | 0.04 | Upgrade
|
| Net Income to Company | -1.18 | -15.18 | -11.73 | -10.72 | -10.95 | -16.11 | Upgrade
|
| Minority Interest in Earnings | 0 | 0 | 0 | - | 0 | 0 | Upgrade
|
| Net Income | -1.18 | -15.18 | -11.73 | -10.72 | -10.95 | -16.11 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.21 | 2.04 | - | 0.66 | - | - | Upgrade
|
| Net Income to Common | -1.39 | -17.22 | -11.73 | -11.39 | -10.95 | -16.11 | Upgrade
|
| Shares Outstanding (Basic) | 53 | 31 | 29 | 24 | 14 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 53 | 31 | 29 | 24 | 14 | 9 | Upgrade
|
| Shares Change (YoY) | 75.79% | 5.31% | 22.80% | 66.02% | 68.80% | 2.72% | Upgrade
|
| EPS (Basic) | -0.03 | -0.56 | -0.40 | -0.48 | -0.76 | -1.89 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.56 | -0.40 | -0.48 | -0.76 | -1.89 | Upgrade
|
| Free Cash Flow | -9.73 | -9.05 | -10.24 | -8.31 | -9.35 | 4.23 | Upgrade
|
| Free Cash Flow Per Share | -0.18 | -0.29 | -0.35 | -0.35 | -0.65 | 0.50 | Upgrade
|
| Gross Margin | - | -181.71% | 100.00% | 99.89% | 98.99% | 91.74% | Upgrade
|
| Operating Margin | -1678790.98% | -17441.81% | -2269.07% | -1170.60% | -1666.48% | -833.57% | Upgrade
|
| Profit Margin | -227780.33% | -26221.65% | -2207.08% | -1244.31% | -1664.30% | -1378.02% | Upgrade
|
| Free Cash Flow Margin | -1594888.03% | -13784.28% | -1927.21% | -908.15% | -1422.07% | 361.67% | Upgrade
|
| EBITDA | -10.13 | -11.36 | -11.98 | -10.64 | -10.82 | -9.6 | Upgrade
|
| D&A For EBITDA | 0.11 | 0.1 | 0.08 | 0.07 | 0.14 | 0.15 | Upgrade
|
| EBIT | -10.24 | -11.45 | -12.06 | -10.71 | -10.96 | -9.75 | Upgrade
|
| Revenue as Reported | 0 | 0.07 | 0.53 | 0.92 | 0.66 | 1.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.